NEW YORK (GenomeWeb) – Swiss contract research firm Intomics said today that it has inked an agreement to collaborate with Actelion Pharmaceuticals on research into neurodegenerative diseases.
Intomics said that the partners will apply a systems biology approach to gain a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level with a long-term goal of facilitating better treatments for patients with such diseases.
Terms of the agreement were not disclosed.
Intomics is a contract research organization that applies its expertise in biomedical analysis and mining, bioinformatics, and systems biology to help pharmaceutical firms increase their success rates in developing drug therapies.